<DOC>
	<DOCNO>NCT01030731</DOCNO>
	<brief_summary>The purpose study characterize pharmacokinetics ( drug absorb body , distribute within body remove body time ) ceftobiprole single 250-mg intravenous ( IV ) infusion ( give directly vein ) 2 hour , dialysis patient end-stage renal disease ( ESRD ) require hemodialysis healthy volunteer .</brief_summary>
	<brief_title>Pharmacokinetic Study , Ceftobiprole , Healthy Volunteers , Healthy Patients With End Stage Renal Disease</brief_title>
	<detailed_description>The purpose study characterize pharmacokinetics ( drug absorb body , distribute within body remove body time ) ceftobiprole single 250-mg intravenous ( IV ) infusion ( give directly vein ) 2 hour , dialysis patient end-stage renal disease ( ESRD ) require hemodialysis healthy volunteer . This Phase 1 , open label study ( patient involve know identity drug ) . Healthy volunteer give single 2-hour infusion 250 mg ceftobiprole ; patient ESRD hemodialysis give 2-hour infusion 250 mg ceftobiprole 3 hour either dialysis immediately dialysis . Plasma urine sample assay ceftobiprole . Samples collect 48 hour period time . Safety evaluation include monitor adverse event , clinical laboratory test ( hematology serum chemistry patients/volunteers , urinalysis healthy volunteer subject ) , pregnancy testing , vital sign , physical examination , record concomitant medication . Healthy volunteer give single 2-hour infusion 250 mg ceftobiprole ; patient ESRD hemodialysis give 2-hour infusion 250 mg ceftobiprole 3 hour either dialysis immediately dialysis .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Skin Diseases , Infectious</mesh_term>
	<mesh_term>Staphylococcal Skin Infections</mesh_term>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Ceftobiprole</mesh_term>
	<mesh_term>Ceftobiprole medocaril</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<criteria>Healthy volunteer hemodialysis patient stable physical condition diagnosis ESRD require hemodialysis treatment 3 time per week History repeat severe nausea History infection hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) Recent febrile illness</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Renal Dialysis , Ceftobiprole</keyword>
	<keyword>Skin soft tissue Infections</keyword>
	<keyword>Staphylococcal Skin Infections</keyword>
	<keyword>Streptococcal Infection</keyword>
</DOC>